Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448922) titled 'A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Condition:
Advanced Gynecological Malignancies
Intervention:
Drug: SKB518 for injection
Drug: Carboplatin (AUC 5)
Drug: Bevacizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 25, 2026
Target Sample Size: ...